DPP4 and type 2 diabetes mellitus: In conclusion, dapagliflozin, when compared with DPP‐4 inhibitor treatment, was associated with a lower risk of MACE, heart failure and all‐cause mortality in a real‐world T2D population, where 23% had previously established CV disease.